United States. Securities and Exchange Commission
Xoma Corp.'s recent SEC filing highlights the company's focus on developing pharmaceutical preparations. The filing, made on June 5, 2015, reveals the company's SIC code and contact information. This document submission underscores the importance of transparency in the financial industry, as it provides stakeholders
United States. Securities and Exchange Commission
According to a U.S. Securities and Exchange Commission (SEC) filing, Sunesis Pharmaceuticals Inc. reported significant corporate changes on June 10, 2015. The company is a pharmaceutical manufacturer with its main operations in South San Francisco, California. As a publicly-traded company, Sunesis Pharmaceuticals is required to submit regular financial statements
United States. Securities and Exchange Commission
Xoma Corp., a pharmaceutical company with operations in Berkeley, CA, filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on June 1, 2015, detailing the company's pharmaceutical preparation activities. As a company listed under the SIC code 2834, Pharmaceutical Preparations, Xoma Corp. is required
United States. Securities and Exchange Commission
Vivus Inc., a pharmaceutical company, has submitted a Form 4 filing to the U.S. Securities and Exchange Commission (SEC) as required by law. The filing, dated May 29, 2015, discloses changes in ownership and transactions involving the company's equity securities. As a publicly-traded company, Vivus Inc. is
United States. Securities and Exchange Commission
A U.S. Securities and Exchange Commission filing by Xoma Corp. was submitted on May 22, 2015, through Form 4, which is a document that discloses the ownership stakes of directors, officers, or shareholders with more than 10% equity in a company. The filing, with the SEC file number 0000791908-15-000065,
United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc. has made a regulatory filing with the Securities and Exchange Commission (SEC) detailing the company's pharmaceutical preparations, as per the source material. The filing, which was posted on May 21, 2015, provides information on the company's equity securities and ownership. According to the
United States. Securities and Exchange Commission
Xoma Corp. has made a submission to the U.S. Securities and Exchange Commission (SEC) regarding its ownership in Pharmaceutical Preparations, according to a recent filing. The company, which has its headquarters located at 2910 SEVENTH ST, BERKELEY CA 94710, has a SIC code of 2834 and is registered under
United States. Securities and Exchange Commission
Sciclone Pharmaceuticals Inc. has reported a material event to the Securities and Exchange Commission (SEC) in the form of a Form 8-K filing, dated April 6, 2015. As a pharmaceutical company under the SIC code 2834, this filing is a critical document for investors and security holders, providing current information
United States. Securities and Exchange Commission
Regen Biopharma Inc., a publicly traded company in the pharmaceutical preparations industry, filed a significant document with the U.S. Securities and Exchange Commission (SEC) on March 24, 2015. The filing, designated as Form 8-K, reported material events and corporate changes that were not previously disclosed to investors or security
United States. Securities and Exchange Commission
Xoma Corp. has made a new filing with the Securities and Exchange Commission (SEC) detailing a significant event in the pharmaceutical industry. According to the filing, Xoma Corp. has engaged in a notable transaction within the company, which is outlined in the document. This filing provides valuable insight into the
United States. Securities and Exchange Commission
The U.S. Securities and Exchange Commission (SEC) has denied efforts by Gilead Sciences and Vertex Pharmaceuticals to block shareholder resolutions asking for greater transparency around the management and mitigation of business risks from rapidly increasing U.S. drug prices. The shareholder resolutions, filed by the UAW Retiree Medical Benefits
United States. Securities and Exchange Commission
Vertex Pharmaceuticals Inc., a leading developer of innovative medicines for the treatment of serious diseases, recently filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on March 6, 2015. The filing reports a director-officer's ownership and transactions of equity securities. As a publicly-traded company,
